相关实验视频
Updated: Jun 25, 2025

07:01
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
84.9K
缺氧和能量代谢重编程之间的反循环加剧了癌细胞的放射电阻
Zheng Shi1,2,3,4, Cuilan Hu1,2,3,4, Xiaogang Zheng1,2,3,4
1Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.
Experimental hematology & oncology
|May 22, 2024
概括
缺氧和代谢重编程驱动癌症的辐射抵抗. 针对这些过程之间的反循环提供了一个有希望的策略,以提高放射治疗对瘤的有效性.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 放射治疗研究 放射治疗研究
背景情况:
- 放射治疗是一种主要的癌症治疗方法,但它的有效性通常受到瘤细胞的放射电阻的限制.
- 瘤缺氧和代谢重编程 (例如,华堡效应) 是癌症进展和放射电阻的关键驱动因素.
- 缺氧源于血管生成不足,导致缺氧,从而保护癌细胞免受辐射.
研究的目的:
- 综合审查将低氧和代谢重编程与癌症放射电阻联系在一起的机制.
- 探索这些因素之间的相互作用及其对治疗结果的影响.
- 确定克服放射电阻的潜在治疗点.
主要方法:
- 文献综述和综合目前关于缺氧,代谢重编程和放射电阻的研究.
- 详细讨论潜在的分子途径,包括DNA修复,癌症干细胞,氧化应激,自,血管生成和免疫逃逸.
- 分析代谢重编程和缺氧之间的拟议反循环.
主要成果:
- 低氧和新陈代谢重编程通过各种细胞机制显著导致放射电阻.
- 在能量代谢和缺氧之间存在一个关键的反循环,加剧了瘤的放射电阻.
- 涉及的具体途径包括DNA修复,癌症干细胞活动,氧化应激,自,血管生成和免疫逃避.
结论:
- 了解缺氧和代谢重编程之间的复杂关系对于改善癌症放射治疗至关重要.
- 同时针对这些过程和其他瘤特定途径之间的反循环,为克服放射电阻提供了一个可行的策略.
- 本综述提供了对瘤辐射敏感性和进展的见解,指导了未来的治疗开发.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Electron Transport Chain: Complex I and II
13.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

